1. Home
  2. BCDA vs CERO Comparison

BCDA vs CERO Comparison

Compare BCDA & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • CERO
  • Stock Information
  • Founded
  • BCDA N/A
  • CERO 2017
  • Country
  • BCDA United States
  • CERO United States
  • Employees
  • BCDA N/A
  • CERO N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • CERO
  • Sector
  • BCDA Health Care
  • CERO
  • Exchange
  • BCDA Nasdaq
  • CERO Nasdaq
  • Market Cap
  • BCDA 7.9M
  • CERO 8.4M
  • IPO Year
  • BCDA N/A
  • CERO N/A
  • Fundamental
  • Price
  • BCDA $2.54
  • CERO $1.92
  • Analyst Decision
  • BCDA Strong Buy
  • CERO
  • Analyst Count
  • BCDA 1
  • CERO 0
  • Target Price
  • BCDA $25.00
  • CERO N/A
  • AVG Volume (30 Days)
  • BCDA 54.1K
  • CERO 787.1K
  • Earning Date
  • BCDA 03-26-2025
  • CERO 02-20-2025
  • Dividend Yield
  • BCDA N/A
  • CERO N/A
  • EPS Growth
  • BCDA N/A
  • CERO N/A
  • EPS
  • BCDA N/A
  • CERO N/A
  • Revenue
  • BCDA $71,000.00
  • CERO N/A
  • Revenue This Year
  • BCDA N/A
  • CERO N/A
  • Revenue Next Year
  • BCDA N/A
  • CERO N/A
  • P/E Ratio
  • BCDA N/A
  • CERO N/A
  • Revenue Growth
  • BCDA N/A
  • CERO N/A
  • 52 Week Low
  • BCDA $0.32
  • CERO $1.76
  • 52 Week High
  • BCDA $5.70
  • CERO $1,238.00
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 56.72
  • CERO 34.43
  • Support Level
  • BCDA $2.12
  • CERO $1.76
  • Resistance Level
  • BCDA $2.73
  • CERO $3.18
  • Average True Range (ATR)
  • BCDA 0.22
  • CERO 0.38
  • MACD
  • BCDA 0.03
  • CERO 0.30
  • Stochastic Oscillator
  • BCDA 58.21
  • CERO 19.72

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

Share on Social Networks: